...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Internal medicine journal >The current status of targeted therapy for non-small cell lung cancer.
【24h】

The current status of targeted therapy for non-small cell lung cancer.

机译：非小细胞肺癌靶向治疗的当前状态。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Lung cancer accounts for more cancer-related deaths than any other malignancy in Australia and worldwide. Non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancers and is associated with a 5-year survival of only 15%. Treatment with platinum-based doublets in the first-line setting and single agent chemotherapy in the second-line setting has improved survival and quality of life in patients with NSCLC. However, the benefits associated with chemotherapy are modest and serve to stress the need for novel therapeutic approaches. In the last decade a range of targeted therapies has been evaluated in NSCLC. Dramatic and often durable responses were seen in patients treated with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) gefitinib and erlotinib particularly in females, non-smokers, patients of East Asian ethnicity and those with adenocarcinomas - a group subsequently found to be enriched for tumours with activating EGFR mutations. Large randomized phase III trials have since established a role for EGFR TKI in the second- and third-line setting as well as a potential role for the monoclonal antibodies bevacizumab and cetuximab, directed at vascular endothelial growth factor and EGFR, respectively, in the combination with chemotherapy in the first-line setting. Recently it has been shown that patients with EGFR mutations may benefit from gefitinib in the first-line setting. Other promising agents under evaluation are inhibitors of the insulin-like growth factor-1 receptor and inhibitors of recently described ALK gene rearrangements.
机译：肺癌占任何与澳大利亚和全球的任何其他恶性肿瘤有关的死亡。非小细胞肺癌（NSCLC）占肺癌的约85％，与5年生存率仅为15％。在第一线凝固中用基于铂的双峰的处理和第二线凝固中的单药化疗在NSCLC患者中提高了生存和生活质量。然而，与化疗相关的益处是适度的，有助于强调新的治疗方法的需求。在过去的十年中，在NSCLC中已经评估了一系列目标疗法。用表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）吉非替尼和奥尔洛替尼治疗的患者中，特别是在雌性，非吸烟者，东亚种族患者和腺癌患者的患者中看到了戏剧性和经常持久的响应。一组随后发现富含激活EGFR突变的肿瘤。自从在第二和第三线设置中建立了EGFR TKI的大型试验，以及单克隆抗体贝伐单抗和西妥昔单抗的潜在作用，分别在组合中分别为血管内皮生长因子和EGFR的潜在作用用化疗在一线设置中。最近，已经表明，EGFR突变的患者可以在一线设置中受益于Gefitinib。在评价中的其他有前途的药剂是胰岛素样生长因子-1受体和抑制剂的抑制剂最近描述的ALK基因重排。

著录项

  • 来源
    《Internal medicine journal》 |2010年第9期|共8页
  • 作者

    Francis H; Solomon B;

  • 作者单位

    Division of Haematology and Medical Oncology Peter MacCallum Cancer Centre Melbourne Victoria Australia.;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 内科学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号